Triumph Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.31K Hold
34
– – ﹤0.01% 1517
2026
Q2
$3.05K Hold
34
– – ﹤0.01% 1492
2026
Q1
$2.69K Hold
34
– – ﹤0.01% 1489
2025
Q4
$2.79K Buy
+34
New +$2.63K ﹤0.01% 1412

Other funds holding PBE

Triumph Capital Management's PBE Position: Q3 2026 in Review

Triumph Capital Management held its Invesco Biotechnology & Genome ETF (PBE) position steady in Q3 2026 at 34 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1517.

Triumph Capital Management first reported a position in PBE in Q4 2025 and has held it in 4 quarters since. 122 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

  • Triumph Capital Management held 34 shares of Invesco Biotechnology & Genome ETF worth $3.31K as of Q3 2026.
  • Triumph Capital Management left its Invesco Biotechnology & Genome ETF share count unchanged in Q3 2026.
  • Invesco Biotechnology & Genome ETF made up ﹤0.01% of Triumph Capital Management's portfolio in Q3 2026, its #1517 holding.
  • Triumph Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q4 2025 and has held it in 4 quarters since.
  • 122 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on Triumph Capital Management's 13F filing for Q3 2026, filed 14 Oct 2026.